Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series - Scorecard - MDSpire
Clinical Scorecard: Enterocolitis Associated with Immune Effector Cells Following BCMA-Targeted CAR T-Cell Therapy: Findings from a Multicenter Case Series
At a Glance
Category
Detail
Condition
Key Mechanisms
Dysregulated T-cell activity resembling autoimmune diseases or graft-versus-host disease (GVHD), with potential overlap with common variable immunodeficiency (CVID).
Target Population
Care Setting
Key Highlights
High mortality rate of 37% attributed to IEC-EC-related complications, independent of myeloma progression.
Guideline-Based Recommendations
Diagnosis
Exclude infectious causes before diagnosing IEC-EC.
Utilize endoscopic evaluation (esophagogastroduodenoscopy and/or colonoscopy) for confirmation.
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Responses to treatment were limited, with many patients experiencing prolonged symptoms; specify outcomes for systemic corticosteroids, infliximab, and ruxolitinib.
Clinical Best Practices
Early identification and management of gastrointestinal symptoms post-CART.
Consider multidisciplinary approaches involving gastroenterology, oncology, and nutrition for managing IEC-EC complications.
by Sandra Susanibar-Adaniya, Benjamin A. Derman, Adam D. Cohen, Dan T. Vogl, Shambavi Richard, Adriana Rossi, Matthew J. Frigualt, Andrew J. Yee, Binod Dhakal, Noffar Bar
U.S. News & World Report has recognized Dana-Farber/Boston Children’s Cancer and Blood Disorders Center as the #1 pediatric cancer program in the nation in its 2026-2027 Best Children’s Hospitals report.
